Olzic Plus 20mg/5mg Tablet is a combination pharmaceutical formulation containing Fluoxetine 20mg and Olanzapine 5mg, indicated for the treatment of major depressive disorder with psychotic features, treatment-resistant depression, and certain bipolar disorders. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), enhances serotonergic neurotransmission by inhibiting the reuptake of serotonin in the central nervous system, thereby improving mood and alleviating depressive symptoms. Olanzapine, an atypical antipsychotic, exhibits antagonistic activity at dopamine D2 and serotonin 5-HT2A receptors, contributing to its efficacy in managing psychotic symptoms and mood stabilization. The synergistic action of these agents addresses both affective and psychotic components of complex psychiatric conditions. Olzic Plus should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include weight gain, sedation, dry mouth, gastrointestinal disturbances, and extrapyramidal symptoms. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizure disorders. Regular monitoring of metabolic parameters and mental status is recommended during therapy. Olzic Plus is contraindicated in individuals with hypersensitivity to its components and should not be used concomitantly with monoamine oxidase inhibitors. This combination therapy offers a comprehensive approach for patients requiring both antidepressant and antipsychotic treatment modalities.